Novacyt (France) Executives
| ALNOV Stock | EUR 0.59 0.01 1.72% |
Novacyt employs about 210 people. The company is managed by 7 executives with a total tenure of roughly 490 years, averaging almost 70.0 years of service per executive, having 30.0 employees per reported executive. Discussion of Novacyt's management performance can provide insight into the enterprise performance.
| Steve Gibson Executive Member of the Executive Team, Group Financial Controller |
| David Franks Insider Chief Officer |
Novacyt |
Novacyt Management Team Effectiveness
The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt's management efficiency ratios could be used to measure how well Novacyt manages its routine affairs as well as how well it operates its assets and liabilities.Novacyt Workforce Comparison
Novacyt is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 759. Novacyt totals roughly 210 in number of employees claiming about 28% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07. Novacyt Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novacyt Price Series Summation is a cross summation of Novacyt price series and its benchmark/peer.
Novacyt Notable Stakeholders
A Novacyt stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novacyt often face trade-offs trying to please all of them. Novacyt's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novacyt's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steve Gibson | Member of the Executive Team, Group Financial Controller | Profile | |
| David Franks | Chief Officer | Profile | |
| Grald Ulrich | Chief Devel | Profile | |
| James McCarthy | Acting CFO | Profile | |
| Wendy Karban | Member of the Executive Team, Group Human Resource Manager | Profile | |
| Bryan Close | Chief Officer | Profile | |
| Paul Oladimeji | Group RD | Profile |
About Novacyt Management Performance
The success or failure of an entity such as Novacyt often depends on how effective the management is. Novacyt management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novacyt management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novacyt management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people.
Novacyt Workforce Analysis
Traditionally, organizations such as Novacyt use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novacyt within its industry.Novacyt Manpower Efficiency
Return on Novacyt Manpower
| Revenue Per Employee | 456.1K | |
| Revenue Per Executive | 13.7M | |
| Net Loss Per Employee | 46.3K | |
| Net Loss Per Executive | 1.4M |
Additional Tools for Novacyt Stock Analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.
Recommendations on macroaxis.com are based on what is currently trending. Macroaxis LLC is not a registered investment advisor or broker/dealer.
The information on the site should be used for informational purposes only and is not investment advice.
more